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IncreasedUrinary Excretionof Digoxin-likeImmunoreactiveSubstanceby Insulin-Dependent
DiabeticPatients:a Linkagewith Hypertension?
Ottavlo GIampletro, Aldo Clerico, Glovanna Gregorl,Stefanla Bertoll, Maria Grazia Del Chlcca, Roberto MIccoll, Amalla Lucchettl,
Lorella CruschelH, and Renzo Navalesl
Excretionof dlgoxin-likeimmunoreactivity(DLIs)was mea-
sured by AlA in timed overnight urine collectionsfrom 91
normotensivenondiabeticsubjects and 104 normotensive
insulin-dependentdiabetic (IDDM) patients.The mean ± SD
DLIS excretion rate for the diabetic patients significantly
exceeded that for the controls (73 ± 41 vs 63 ± 36 pg/mm,P
= 0.024). In both groups,the mean DLIS excretionrates for
menwere significantlyhigher (P = 0.0014, P = 0.0006) than
forwomen.Inthe controls,the OLIS excretionratesignificantly
correlated with the urinary excretion rate of creatinine (P
<0.01), Na(P <0.05), and K(P <0.05), and with the
subjects’body weight(P <0.01), bodymassindex(P <0.05),
and systolicbloodpressure (P <0.05). In the diabetics,the
DLIS excretion rate was significantlycorrelated with body
weight(P <0.05) and withurinary excretionratesfor albumin
(P <0.01), creatinine (P <0.01), Na(P <0.05), and K(P
<0.05). Our data indicate that: (a) increased amountsof a
cardiacglycoside-likesubstance(or a groupof substances)
are excreted in the urine of lOOM patients; (b) the urinary
excretionof OLIS seems to depend on glomerularfiltration
rate and physicochemicalproperties of glomerular mem-
brane, as well as on subjects’body mass; and (c) because
cardiac glycoside-likesubstances may increase peripheral
vascular resistance, increased urinary excretionof DLIS by
(0DM patientsmay indicatea tendency to develop hyperten-
sion.
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Considerable evidence (1, 2) indicates that increases in
body sodium and expansion of extracellular volume lead to
the release of humoral natriuretic factors. As recently
reviewed (1-4), one of these factors is suggested to be an
endogenous substance having immunological and biological
activities similar to those of the cardiac glycosides. This
endogenous factor inhibits Na/K-transporting ATPase
(EC 3.6.1.37) in various tissues, including the kidney, and
this causes natriuresis.
Insulin-dependent diabetes mellitus (moM) reportedly is
associated with sodium retention, leading to increases of
exchangeable body sodium (5, 6) and extracellular volume
and a suppression of the renin-angiotensin-aldosterone
system.1 This has been recently confirmed by Feldt-Rasmus-
sen et al. (7). Thus, the release of a substance with cardiac
glycoside-like activity and NafK-ATPase inhibiting ac-
tivity could conceivably be triggered by volume expansion in
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IDDM. In fact, inhibition of Na/KtATPase has been docu-
mented in tissues of experimental diabetic animals and in
diabetic patients (8).
Several studies (for review, see references 1-4) indicate
that, in addition to its natriuretic activity, this cardiac
glycoside-like endogenous factor, by inhibiting Na/K-
ATPase in arterioles, increases the intracellular Na, which
in tm-n increases the intracellular calcium, leading to
increased vascular reactivity. Hence, endogenous factors
with activity similar to that of cardiac glycosidesmay play a
role in the pathogenesis of some forms of hypertension,
especially the low-renin forms (1-4). Such could also be the
case in IDDM.
Hypertension and diabetes mellitus may occur together
(9, 10), and hypertension is more prevalent in diabetic
patients than in the general population (10, 11). Diabetic
nephropathy is considered the main cause of hypertension
in 10DM (12), and blood pressure may begin to increase even
in patients with slight albuminuria, who are at high risk of
developing overt diabetic nephropathy (13). However, the
hypertension-diabetes association in IDDM patients cannot
be entirely secondary to diabetic nephropathy, because
hypertension can already be present in patients with recent
onset of diabetes (14) but without signs of renal involvement
(10, 11). Because of abnormalities in the balance of body
sodium and fluid volume in IDDM patients (5-7), the release
of an endogenous factor with cardiac glycoside-like activity
could play a role in the pathogenesis of non-nephropathic
hypertension in IDDM.
To test the hypothesis that production of a substance with
cardiac glycoside-like activity might be increased in IDDM
uncomplicated by overt diabetic nephropathy or hyperten-
sion, we used a sensitive A method (15,16) to measure the
urinary excretion rate of a substance with digoxmn-like
immunoreactivity (Dus) in 104 normotensive, non-nephro-
pathic 10DM patients and 91 nondiabetic control subjects. In
each of these groups (controls and diabetics), we also mea- -
sured the urinary albumin excretion rate, an early and
sensitive predictor of clinical diabetic nephropathy (13), and
some other clinical, metabolic, and renal characteristics of
the subjects, to determine their relationship, if any, with
urinary DLIS excretion rate.
Materlal8 and Methods
Subjects. Ninety-one nondiabetic, normotensive subjects
(46 men, 45 women) and 104 normotensive, Albustix-nega-
tive (Miles GmbH, Sparte Ames, Frankfurt, F.RG.) IDDM
patients (41 men, 63 women) participated in our study. No
subject was being treated with digoxin. All subjects had a
normal renal function, as assessed by endogenous creatiine
clearance, and all, except for 10 diabetics, were normoalbu-
minuric. Some other pertinent clinical characteristics are
reported in Table 1. For the slight (“pauci”) albuminuria
threshold, we chose the albumin excretion rate of 30 zg/min,
in accord with Viberti et al. (13). We verified by culturing
that all subjects’ urines were sterile. Of the diabetics, 62
IDOM
8y mass index: body weight/height2. bSignificanUydifferent (P <0.01) from control subjects. csignificdy different (P <0.01) from ioci subjects with AER
<30 gzg/min.Abbreviations: AER, albumin excretion rate; PPG, preprandial plasma glucose; Cr, creatinine.
Table 1. ClinIcal CharacterIstics of Subject8 Studied (Means ± SD)
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Age,y
BMI, kg/rn28
Diabetesduration,y
Insulin,units/day
PPG,mg/L
HbA1C, %
AER, p9/mm
Serum Cr, mg/L
Blood pressure, rnmHg
Systolic
Diastolic
Control sublects
91
30.2 ± 10.1
22.8 ± 3.0
785 ± 118
5.3 ± 0.4
4.6 ± 2.7
8.0 ± 1.0
116.2 ± 9.6
76.9 ± 6.4
AER <30 ,ig/mln
94
31.7 ± 13.2
23.1 ± 3.8
9.6 ± 7.1
53.4 ± 21.2
1589 ± 697b
8.4 ± 18b
6.9 ±
8.0 ± 2.0
120.0± 15.0
75.6 ± 11.8
AER >30 gig/mm
10
37.6 ± 14.6
24.8 ± 3.6
16.0± 4.5
58.2 ± 19.4
1713 ± 619k’
10.0 ± 16b
66.5 ± 3g6b.c
8.0 ± 4.0
122.1 ± 15.0
77.9 ± 7.0
(59.6%) had no signs of retinopathy, 29 (27.9%) had back-
ground retinopathy, and 13(12.5%) had retinal proliferative
lesions. All patients were treated with insulin therapy only,
most of them with multiple insulin injections (the mean
daily doses are listed in Table 1).
Every subject collected urine specimens before going to
bed and upon arising, and the time of collection was exactly
recorded for the calculation of urinary us excretion rate (in
pg/mn) and albumin excretion rate (in g/min). For most of
these subjects we also calculated the urinary excretion rate
for creatiine (mg/mm) and electrolytes (Na and K,
mmollmin). When the same subjects collected more than one
urine specimen on consecutive nights (as did 26 of 104
diabetics and 43 of 91 control subjects), we used for statisti-
cal calculations the mean rate of urinary excretion of each
analyte from the several collections.
DLIS assay. We measured DLIS by a solid-phase RIA (15,
16) in which digoxin dissolved in a buffer containing human
serum albumin, 40 g/L, is used as standard, ‘I-labeled
digoxin is the tracer, and antibody-coated test tubes are
used to separate bound from free digoxin (tracer and coated
test tubes were supplied by Byk Gulden Italia S.p.A.,
Cormano, Italy). To improve the sensitivity and the repro-
ducibility of the assay as well as the stability of standard
curves, we also included human serum albumin, 40 gIL, in
the assay buffer and added the same albumin-containing
buffer to unknown urine samples, to equalize the effect of
albumin on the reaction volume. Results were expressed as
digoxin equivalents. We assayed 0.2-mL urine samples in
duplicate, without dilution or extraction. The mean limit of
detection (95% confidence limit), as determined in 21 sepa-
rate experiments, was 5.38 (SD 1.07) pg per tube. The mean
between-assay CV for DLIS in a urine pool, assayed over 10
months (n = 25), was 12.9% (mean DUS concn, 281.9, SD
36.4 ngIL).
Albumin excretion rate assay. We used an RIA kit (“Albu-
min RIA 100”; Pharmacia AB, Uppsala, Sweden) for assay
of albuminuria in normal subjects and diabetics. This RIA
involves purified human serum albumin as the standard,
‘I-labeled human serum albumin as tracer, and a specific
antiserum to human serum albumin. Bound and free phases
were separated by a solid-phase system (sheep anti-rabbit
IgG, bound to Sepharose). We assayed, in duplicate, 50-p.L
urine samples; the standard curve was based on assays of
solutions containing known amounts of purified human
serum albumin (0.8, 1.6, 4, 8, 16, 40, and 80 mgIL). The RIA
was not subject to interference from bovine serum albumin,
transferrin, or human immunoglobulins. The mean (n = 25)
limit of detection of this RIA was 0.28 (SD 0.13) mg/L. The
between-assay CV for a wide range of albumin concentra-
tions in several pooled-urine specimens ranged between 5%
and 15%.
Other methods. We measured glucose in plasma by a
glucose oxidase (EC 1.1.3.4) method, in a glucose analyzer
(Beckman Instruments, Fullerton, CA). To quantify glycat-
ed hemoglobin (HbA1), we used an automated HPLC ana-
lyzer system (HA-8110; Daiichi Kagaku, Kyoto, Japan).
Creatinine in serum and urine was measured by the Jaff#{233}
reaction (Astra 8, Beckman), urinary sodium and potassium
by flame photometry (Model 435 flame photometer; Corning
Medical, Healsted, Essex, U.K.).
Statistical analysis. All values for samples and the other
data for quality control of the two RIA systems were
calculated by use of previously described computer pro-
grams (17, 18).
The interpolation of the dose-response curves was calcu-
lated by using a four-parameter logistic function (18).
For statistical analysis for comparison of groups by para-
metric and nonparametric tests and calculation of simple
and multiple regression coefficients we used a Mackintosh
SE personal computer with the “512 + Stat-View” and
“Stat-View” programs. All data are reported as mean ± SD.
Results
Figure 1 shows the frequency distribution of values for
urinary Dus excretion observed in the diabetic patients and
matched controls. The values for either group were not
normally distributed.
The mean DLIS excretion rate for men significantly ex-
ceeded that for women, both in control subjects and diabetics
(control subjects: women 51.6 ± 21.4 pg/mm vs men 73.7 ±
42.7 pg/mm, P = 0.0006 by the Mann-Whitney U two-tailed
test; diabetics: women 65.6 ± 39.2 pg/mm vs men 86.7 ±
41.4 pg/mm, P = 0.0014).
Diabetic patients (men and women) had a mean DLIS
excretion rate significantly higher than controls (73.09 ±
41.21 pg/mn vs 62.80 ± 35.49 pg/mm, P = 0.024 by the
Mann-Whitney U two-tailed test). Even taking into account
the sex of subjects, diabetics had a mean DUS excretion rate
significantly higher than controls (diabetic vs control men:
P = 0.038; diabetic vs control women: P = 0.0316, Mann-
Whitney U two-tailed test) (Figure 2).
After the 10 paucialbuminuric patients (albumin excre-
tion rate >30 gtg/min) were excluded from statistical analy-
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In diabetic patients, the DLIS excretion rate significantly
correlated with the excretion rates for urinary albumin,
creatinine, Na, and K’1’,and also with the body weight of
patients, but not with their age, blood pressure, diabetes
duration, HbA1, serum creatiine, or presence and severity
of retinopathy (Table 2). In the multiple regression analysis,
not only urinary creatiine excretion rate (the first variable
entered), but also albumin excretion rate significantly con-
tributed to the correlation with DLIS excretion rate in
diabetic patients (r = 0.517, P <0.001, n = 63). The
correlations between Dus excretion rate and albumin excre-
tion rate, and DLIS excretion rate and creatinine excretion
rate, respectively, were still present also after the 10 pauci-
albuminuric patients had been excluded from the regres-
320 sion.
Discussion
Because DLIS concentrations in plasma of normal adults
and hypertensive patients are often near the detection limit
of our RIA method (about 25 pg/mL, digoxin equivalents),
direct assay of plasma samples (i.e., without extraction and
concentration of samples) is not indicated (19). On the
contrary, because urine has three- to 10-fold higher concen-
trations of DLI5 than those in blood, assay of urine samples
seems preferable for clinical studies (19). The present study
is the first one evaluating the urinary excretion of DLIS in a
large number of normal subjects and IDDM patients. The
timed overnight urine collection was chosen because it is
easier to perform than 24-h collection, and because physical
activity affects values for DLIS in both serum and urine (20,
21).
We measured Dus values by a very sensitive RIA method
specifically modified in our laboratory for the assay of
digoxin-like inununoreactivity (16, 19). As previously re-
ported for extracts of plasma of adults, pregnant women,
and newborns, the results obtained with this RIA correlate
well with those by a radioreceptor assay based on binding of
[3H]ouabain to human erythrocytes (22). So this RIA can
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sis, diabetics as a group showed still a significantly higher
DLIS excretion rate (71.036 ± 37.449, n = 94, by Mann-
Whitney one-tailed test P = 0.032) than control subjects.
The 10 paucialbuminuric patients showed a DLIS excretion
rate (100.88 ± 63.63 pg/mm) significantly higher than the
94 normoalbuminuric diabetics (P <0.05) and the control
subjects (P <0.006) by the Mann-Whitney one-tailed test.
Therefore, the DLIS excretion rate values of three groups
(controls, normoalbuminuric, and paucialbuminuric diabet-
ics) do not come from the same population (Kruskal-Wallis
one-way analysis, P <0.02). The paucialbuminuric patients
who, all except one, had retinopathy (three background, six
proliferative), also showed significantly higher values for
duration of diabetes (16 ± 4 years, by t-test P <0.01) and
HbA1C (10% ± 2%, by t-test P <0.02) than did normoalbu-
minuric diabetics. Finally, blood pressure tended to be
higher (t-test, P >0.05) in paucialbuminuric (systolic 122.1
± 14.7 mmHg; diastolic, 77.9 ± 7.0 mmHg) than in nor-
moalbummnuric diabetic patients [119.8 (SD 14.7) and 75.6
(SD 11.8) mm}Ig, respectively] (Table 1).
In the control group, urinary DLIS excretion rate signifi-
cantly correlated with urinary creatinine, Na, and K’
excretion rates, as well as with subjects’ body weight, body
mass index, and systolic blood pressure, but not with their
age, albumin excretion rate, serum creatinine, and diastolic
blood pressure (Table 2). In the stepwise regression analysis,
only urinary creatinine excretion rate significantly contrib-
uted to regression.
nerve cell
I
volume expension
I RTERIOLEIncreesed DLIS produCtlon
Controls
r
Age
Body weight
Body mass index
Systolicblood pressure
Diastolicblood pressure
Diabetes duration
HbA1C
Albumin excretion rate
Na”’excretionrate
K excretionrate
Creatinine excretion rate
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flea 1986).
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Correlationsare significant at P <001, 1)P<005.
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detect, to some extent, substances with both immunological
and biological activity similar to that of cardiac glycosides.
Insulin-dependent diabetic patients, normotensive and
with normal renal function, were chosen for the study
because DLIS can be increased in biological fluids of patients
with essential hypertension and with renal function impair-
ment (3, 4).
In the present study, the urinary DLIS excretion rate was
significantly smaller in women than in men, both in diabet-
ics and controls, and was significantly related to subjects’
body weight and body mass index. Evidently, mis urinary
output depends closely on subjects’ body mass and frame.
Urinary DLISexcretion rate was significantly higher in
IDDMthan in nondiabetic subjects. The overlap between the
two groups (Figures 1 and 2) may be because we studied
only normotensive diabetic patients, most of whom were in
fair or good metabolic control and none of whom had clinical
diabetic nephropathy. Preliminary findings from the 10
paucialbuminuric patients seem to suggest that 10DM pa-
tients with overt or incipient (23) nephropathy and (or) in
poor metabolic control could have greater DLIS excretion in
urine. The 10 paucialbuminuric diabeticstend also to have
marginally increased blood pressure, although still within
the normal range, in accord with previous reports (23). This
marginally increased blood pressure conceivably could play
a role in determining the increased urinary nus excretion.
Owing to its significant correlation with creatinine excre-
tion rate in controls, and with creatinine excretion rate and
albumin excretion rate in diabetic patients, the urinary
excretion of DLIS seems conceivably to depend both on
glomerular ifitration and on physicochemical properties of
glomerular membrane.
Among mechanisms that may contribute to the abnormal-
ity in the balance of body sodium and fluid volume reported
in 10DMpatients (5-7), peripheral hyperinsulinemia caused
by exogenous insulin administration may be included (7).
The hyperinsulinemia stimulates reabsorption of sodium by
the kidney (7,23-25), ultimately leading to an increase in
exchangeable sodium and to an expanded extracellular
volume (5-7, 25). In addition, diabetic patients, mainly
insulin-dependent ones, tend to have high circulating con-
centrations of somatotropin (26), which itself stimulates
tubular reabsorption of sodium (27,28). Continued expan-
sion of the body extracellular volume by sodium retention
can thus stimulate the release of a circulating digitalis-like
substance in 10DM patients (1-4). The significant correlation
we found between urinary excretion rates of DLIS and Na” is
Table 2. CoefficIents of Correlation between Urinary
ous ExcretIon Rate and Other ClInical Characteristics
In Control Subjects and Diabetic Patients
red cell
inhi bitton 01 Ne/K-ATPsSc INCREASEDNe
_I
Iincressed peripherel resistencesHYPERTENSION
Fig.3.Working hypothesis for thepathogenesis ofhypertensionin lOOM
in harmony with this hypothesis. In addition, Na”’/K”-
ATPase activity has been found to be decreased in certain
tissues of experimental diabetic animals-peripheral
nerves, sarcolemma, blood-brain barrier (8,29,30,31)-and
in erythrocytes of type 1 diabetic patients (32). These
findings suggest that, in 10DM, the tissues are probably in
contact with increased amounts of an endogenous inhibitor
of Na/K-ATPase.
Diabetes mellitus and hypertension are chronic condi-
tions that frequently coexist (9). The increased urinary
excretion rate of digoxin-like immunoreactivity in a group
of normotensive, non-nephropathic 10DM patients could lead
us to consider the increased urinary DLIS as a link with
hypertension in 10DM.
As a working hypothesis (Figure 3), the release of an
endogenous natriuretic factor with biological and immuno-
logical cardiac properties could cause a stable hypertension
in genetically susceptible 10DM patients (33-35).
Further longitudinal studies are needed to definitively
disclose and assess the pathophysiological and clinical rele-
vance of increased urinary ohs excretion in IDDM patients.
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